Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer
- PMID: 25836941
- DOI: 10.1016/j.hoc.2014.11.003
Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer
Abstract
Recent studies revealed that muscle-invasive bladder cancers segregate into intrinsic basal and luminal subtypes that are similar to those described for breast cancer. Each subtype is enriched with potentially clinically actionable genomic alterations and epigenetic signatures; there are associations between tumor subtype and sensitivity to conventional cisplatin-based chemotherapy. The authors review biological and clinical characteristics of the intrinsic subtypes and describe their implications for the development of conventional and targeted agents. The role that tumor plasticity seems to play in basal and luminal bladder cancer biology and its potential effects on the development of therapeutic resistance is also discussed.
Keywords: Basal and luminal; Neoadjuvant chemotherapy; Urothelial cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Genetic subtypes of invasive bladder cancer.Curr Opin Urol. 2015 Sep;25(5):449-58. doi: 10.1097/MOU.0000000000000200. Curr Opin Urol. 2015. PMID: 26218634 Review.
-
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.EBioMedicine. 2016 Oct;12:105-117. doi: 10.1016/j.ebiom.2016.08.036. Epub 2016 Aug 25. EBioMedicine. 2016. PMID: 27612592 Free PMC article.
-
Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20. Eur Urol. 2018. PMID: 30033047
-
Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.Oncotarget. 2016 Dec 6;7(49):80164-80174. doi: 10.18632/oncotarget.13284. Oncotarget. 2016. PMID: 27845906 Free PMC article.
-
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer.Cancer Treat Rev. 2017 Mar;54:1-9. doi: 10.1016/j.ctrv.2017.01.002. Epub 2017 Jan 11. Cancer Treat Rev. 2017. PMID: 28135623 Review.
Cited by
-
Traditional Classification and Novel Subtyping Systems for Bladder Cancer.Front Oncol. 2020 Feb 7;10:102. doi: 10.3389/fonc.2020.00102. eCollection 2020. Front Oncol. 2020. PMID: 32117752 Free PMC article. Review.
-
Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.Curr Treat Options Oncol. 2018 May 28;19(7):36. doi: 10.1007/s11864-018-0551-z. Curr Treat Options Oncol. 2018. PMID: 29808294 Review.
-
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.Bladder Cancer. 2016 Apr 27;2(2):165-202. doi: 10.3233/BLC-160053. Bladder Cancer. 2016. PMID: 27376138 Free PMC article.
-
Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score.World J Urol. 2024 Mar 14;42(1):155. doi: 10.1007/s00345-024-04798-5. World J Urol. 2024. PMID: 38483580
-
The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Transl Cancer Res. 2020 Oct;9(10):6609-6623. doi: 10.21037/tcr-20-1243. Transl Cancer Res. 2020. PMID: 35117271 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical